Zobrazeno 1 - 7
of 7
pro vyhledávání: '"MA Aranguren"'
Autor:
L. M. Lopez Dominguez, N. Alcorta Lorenzo, MA Aranguren Redondo, E. Uriarte Isacelaya, A. De Diego Sola, O. Maiz-Alonso, J. J. Cancio Fanlo, M.B. Irastorza Larburu, J. M. Belzunegui Otano, C. A. Egues
Publikováno v:
Annals of the Rheumatic Diseases. 80:1141-1142
Background:Biological disease modifying drugs (bDMARD) has allowed a targeted approach to rheumatoid arthritis (RA). Once sustained remission is achieved, the use of bDMARDs at lower doses than indicated in data sheets is considered (optimized treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65410f6c22781a56052d7ccb06afe57e
https://doi.org/10.1136/annrheumdis-2021-eular.3045
https://doi.org/10.1136/annrheumdis-2021-eular.3045
Autor:
G Lizeaga Cundin, J Landa Alberdi, A Lizardi Mutuberria, MP Bachiller Cacho, MJ Garcia de Andoin Barandiaran, L Leunda Eizmendi, MA Aranguren Redondo, A Zurutuza Lopez, M Urretavizkaya Anton, Dan Garcia, T Gonzalez Fernandez
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background In the pivotal authorisation trial of carfilzomib, patients with severe cardiovascular abnormalities (NYHA III or IV), clinically significant and uncontrolled, were not included. Purpose The aim of this study was to analyse the cardiovascu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07be9455dc91bfec14246229bad6b477
https://doi.org/10.1136/ejhpharm-2019-eahpconf.484
https://doi.org/10.1136/ejhpharm-2019-eahpconf.484
Autor:
MB Irastorza, J. Barral, M Ercilla, Paula Carmona, M Umerez, MA Aranguren, A Lizardi, MP Bachiller, M Urretavizcaya
Publikováno v:
European Journal of Hospital Pharmacy. 22:A58.1-A58
Background Respiratory syncytial virus (RSV) infections can be prevented by good hygiene and prophylactic palivizumab, a monoclonal antibody against the fusion protein of VRS. The criteria for selecting patients for palivizumab prescription in our ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d31dc830ce209cdc2273dfbcc2eb5bd
https://doi.org/10.1136/ejhpharm-2015-000639.138
https://doi.org/10.1136/ejhpharm-2015-000639.138
Autor:
MJ Gayan Lera, L Lombera Saez, MP Bachiller Cacho, MP Carmona Oyaga, I Aguirre Zubia, MA Aranguren Redondo, M Ercilla Liceaga, A Lizardi Mutuberria, L Leunda Eizmendi, M Ripa Ciaurriz
Publikováno v:
European Journal of Hospital Pharmacy. 22:A67.3-A68
Background A drug adjustment programme for patients with renal disease was started in 2013 in our hospital. In this system, information from the electronic prescription programme is linked (using an Access application) with information sent by the la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b31622ed32ff785401bf3f16e9745cd
https://doi.org/10.1136/ejhpharm-2015-000639.161
https://doi.org/10.1136/ejhpharm-2015-000639.161
PS-038 Appropriateness of new oral anticoagulant prescriptions: analysis of pharmacist interventions
Autor:
A Lizardi, G Lizeaga, L Leunda, E Esnaola, MP Bachiller, I Agirre, MA Aranguren, K Andueza, M Umerez, Paula Carmona
Publikováno v:
European Journal of Hospital Pharmacy. 22:A151.2-A151
Background New oral anticoagulants are an alternative to acenocoumarol in the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. Purpose To assess the suitability of prescriptions for new oral anticoag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04d49a107341b73b8767ed4ff95d4fb9
https://doi.org/10.1136/ejhpharm-2015-000639.364
https://doi.org/10.1136/ejhpharm-2015-000639.364
Autor:
G Lopez Arzoz, MP Bachiller Cacho, G Liceaga Cundin, MI Fernandez Gonzalez, M.B. Irastorza Larburu, I Aguirre Zubia, O Valbuena Pascual, J Belzunegui Otaño, O. Maiz Alonso, MA Aranguren Redondo
Publikováno v:
European Journal of Hospital Pharmacy. 20:A163.1-A163
Background Drug dosage modifications are a common clinical practise regarding Tumor Necrosis Factor (TNF) blockers, using posologies not specified on the authorised product information summary. This practise has a significant financial impact on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f0e69a8bba70a442b2e69a750cdf6b3
https://doi.org/10.1136/ejhpharm-2013-000276.452
https://doi.org/10.1136/ejhpharm-2013-000276.452
Autor:
MJ Gayan Lera, I Aguirre Zubia, MC Leunda Eizmendi, MA Aranguren Redondo, MC Andueza Granados, G Lizeaga Cundin, M Barrenetxea Zabala
Publikováno v:
European Journal of Hospital Pharmacy. 20:A194.2-A194
Background Computerized physician order entry (CPOE) implementation in hospitals has become an important tool for interactive validation of medical orders as well as a facilitator for pharmacist interventions. However several studies have investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2aa70e682faf299b15df86014ee0c36f
https://doi.org/10.1136/ejhpharm-2013-000276.539
https://doi.org/10.1136/ejhpharm-2013-000276.539